Monto AS - Search Results

1

Comment on "Seroevidence for H5N1 influenza infections in humans: meta-analysis".

Van Kerkhove MD, Riley S, Lipsitch M, Guan Y, Monto AS, Webster RG, Zambon M, Nicoll A, Peiris JS, Ferguson NM. Van Kerkhove MD, et al. Among authors: monto as. Science. 2012 Jun 22;336(6088):1506; author reply 1506. doi: 10.1126/science.1221434. Science. 2012. PMID: 22723396

2

Influenza.

Uyeki TM, Hui DS, Zambon M, Wentworth DE, Monto AS. Uyeki TM, et al. Among authors: monto as. Lancet. 2022 Aug 27;400(10353):693-706. doi: 10.1016/S0140-6736(22)00982-5. Lancet. 2022. PMID: 36030813 Free PMC article. Review.

3

Improving influenza vaccine virus selection: report of a WHO informal consultation held at WHO headquarters, Geneva, Switzerland, 14-16 June 2010.

WHO Writing Group; Ampofo WK, Baylor N, Cobey S, Cox NJ, Daves S, Edwards S, Ferguson N, Grohmann G, Hay A, Katz J, Kullabutr K, Lambert L, Levandowski R, Mishra AC, Monto A, Siqueira M, Tashiro M, Waddell AL, Wairagkar N, Wood J, Zambon M, Zhang W. WHO Writing Group, et al. Influenza Other Respir Viruses. 2012 Mar;6(2):142-52, e1-5. doi: 10.1111/j.1750-2659.2011.00277.x. Epub 2011 Aug 8. Influenza Other Respir Viruses. 2012. PMID: 21819547 Free PMC article.

4

Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use.

Monto AS, McKimm-Breschkin JL, Macken C, Hampson AW, Hay A, Klimov A, Tashiro M, Webster RG, Aymard M, Hayden FG, Zambon M. Monto AS, et al. Antimicrob Agents Chemother. 2006 Jul;50(7):2395-402. doi: 10.1128/AAC.01339-05. Antimicrob Agents Chemother. 2006. PMID: 16801417 Free PMC article.

5

Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice.

Yen HL, Monto AS, Webster RG, Govorkova EA. Yen HL, et al. Among authors: monto as. J Infect Dis. 2005 Aug 15;192(4):665-72. doi: 10.1086/432008. Epub 2005 Jul 15. J Infect Dis. 2005. PMID: 16028136

6

Importance of neuraminidase active-site residues to the neuraminidase inhibitor resistance of influenza viruses.

Yen HL, Hoffmann E, Taylor G, Scholtissek C, Monto AS, Webster RG, Govorkova EA. Yen HL, et al. Among authors: monto as. J Virol. 2006 Sep;80(17):8787-95. doi: 10.1128/JVI.00477-06. J Virol. 2006. PMID: 16912325 Free PMC article.

7

Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility.

Yen HL, Herlocher LM, Hoffmann E, Matrosovich MN, Monto AS, Webster RG, Govorkova EA. Yen HL, et al. Among authors: monto as. Antimicrob Agents Chemother. 2005 Oct;49(10):4075-84. doi: 10.1128/AAC.49.10.4075-4084.2005. Antimicrob Agents Chemother. 2005. PMID: 16189083 Free PMC article.

8

Pandemic influenza: an inconvenient mutation.

Layne SP, Monto AS, Taubenberger JK. Layne SP, et al. Among authors: monto as. Science. 2009 Mar 20;323(5921):1560-1. doi: 10.1126/science.323.5921.1560. Science. 2009. PMID: 19299601 Free PMC article. No abstract available.

9

Protecting the herd from H1N1.

Eisenberg JN, Aiello AE, Spicknall IH, Monto AS, Reingold A. Eisenberg JN, et al. Among authors: monto as. Science. 2009 Nov 13;326(5955):934; author reply 934. doi: 10.1126/science.326.5955.934-a. Science. 2009. PMID: 19965495 No abstract available.

10

Antivirals for influenza in healthy adults.

Monto AS. Monto AS. Lancet. 2006 May 13;367(9522):1571-2; author reply 1573. doi: 10.1016/S0140-6736(06)68684-4. Lancet. 2006. PMID: 16698401 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

366 results

Search Page